Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors

[Display omitted] Aberrant RET kinase signaling is activated in numerous cancers including lung, thyroid, breast, pancreatic, and prostate. Recent approvals of selective RET inhibitors, pralsetinib and selpercatinib, has shifted the focus of RET kinase drug discovery programs towards the development...

Ausführliche Beschreibung